Coming Soon: A Multi-Drug Cocktail for Hepatitis C
November 8, 2010
Bristol-Myers, Gilead Seek AIDS Cocktail Success in Hepatitis C
By Michelle Fay Cortez – Oct 29, 2010
Bristol-Myers Squibb Co. and Gilead Sciences Inc., makers of the top-selling combination pills for AIDS, are trying to duplicate their success to combat another evasive virus, hepatitis C.
The companies are among about a dozen that are developing drug cocktails more effective, less toxic and easier to take than current therapy. Hints of which blends may work will emerge next week, in research presented at a Boston meeting of the American Association for the Study of Liver Disease.
The pill combinations are designed to cure the liver- destroying hepatitis C virus without using interferon, a decades-old shot that causes a year of flu-like symptoms and works in only half of patients.
Continue reading this entire article:
Locteron Triumphs in Phase 2 Hepatitis C Trial
Hepatitis C Interim Study Results Favorable for TMC435